After initially pursuing a career in three-dimensional design and moving into the third sector, I was drawn into the world of statistics due to a passion for disease research particularly in cancer patients.
At HDI I focus mainly on epidemiological studies, collaborating with charities and industry to highlight inequalities and support the development of new treatments.
Outside of work I’m a keen runner, who when not running, can often be found trying to convince others to take up the hobby.
Ovarian cancer audit feasibility pilot
Testing the Simulacrum
Real-world Standing Cohorts
Senior Health Data Analyst
Amy trained in epidemiology at the London School of Hygiene and Tropical Medicine. Whilst there she primarily focussed on non-communicable diseases, using the CPRD database to research treatment changes, adherence to guidelines, and associated factors in COPD patients.
She has experience of working with clinical data directly in an acute trust setting, where at Great Ormond Street she managed the clinical data and analysis for bone marrow transplants, oncology, infectious diseases, rheumatology and immunology.
Her in depth understanding of cancer datasets came from working within an NHS and Public Health England Partnership aiming to reduce inequalities in cancer across London.
These experiences led her to HDI where she works across several epidemiological studies. Her work includes developing real-world standing cohorts, where registration data are linked to treatment datasets to describe treatment pathways, outcomes and adverse effects as a population level comparator for novel therapeutics.
Education and awards:
2017-18: London School of Hygiene and Tropical Medicine
– MSc in Epidemiology (Distinction)
2014-15: Birkbeck University of London
– Graduate Certificate in Applied Statistics
2006-09: Northumbria University Newcastle
– BA Hons (First Class) Three Dimensional Design
- Zalin-Miller A, Jose S, Knott C, Paley L, Tataru D, Morement H, Toledano MB, Khan SA. Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017. World J Gastroenterol. 2023 Jun 28;29(24):3825-3842. doi: 10.3748/wjg.v29.i24.3825. PMID: 37426314; PMCID: PMC10324535.
- Angela Whittle, Betina Blak, Amy Zalin-Miller, Orlaith Condon (2022) ‘Characteristics, treatment patterns and outcomes of patients with newly diagnosed advanced ovarian cancer (aOC) in England’; abstract accepted at the European Society of Gynaecological Oncology (ESGO) and also the International Journal of Gynecological Cancer (BMJ).
- Elsada A., Zalin-Miller A., Knott C., Caravotas L. (2021) ‘A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England’ Wiley Online LIbrary eJHeam. June 2021.
Blak BT, Sharma R, Zalin-Miller A, Jose S, Mare SL. Clinical characteristics, treatments and outcomes in patients diagnosed with hepatocellular carcinoma (HCC) receiving locoregional treatment in England. EASL Liver Cancer Summit. 2023 (Poster).
Zalin-Miller A, Price L, Petit J, Jose S. 2017 Cancer Prevalence for London. British Journal of General Practice. 2020 (Poster).
Zalin-Miller A, Jose S. Hospital Use and Cancer Treatment at the End of Life, for People Dying due to Cancer. Transforming Cancer Services Team and Public Health England. 2020.
Jose S, Zalin-Miller A. Practice Profiles Plus 2019 – key cancer diagnosis and referral indicators for each practice or CCG within each England region. 2020.
Zalin-Miller A, Price L. Bringing together data to better understand people living with a cancer in London. Transformation Partners in Health and Care. 2019 (Blog).
Zalin-Miller A, Jose S. 2017 Cancer Prevalence Dashboard for London. Transforming Cancer Services Teamand Public Health England. 2019.